

CORRESPONDENCE

Children with Covid-19 in Pediatric Emergency Departments in Italy

TO THE EDITOR: On February 20, 2020, the incidence of Covid-19 began to rapidly escalate in Italy. By March 25, Italy had the second highest number of Covid-19 infections worldwide and the greatest number of deaths.¹ Children younger than 18 years of age who had Covid-19 composed only 1% of the total number of patients; 11% of these children were hospitalized, and none died.² The Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) study involved a cohort of 100 Italian children younger than 18 years of age with Covid-19 confirmed by reverse-transcriptase–polymerase-chain-reaction testing of nasal or nasopharyngeal swabs who were assessed between March 3 and March 27 in 17 pediatric emergency departments. Here, we describe the results of the CONFIDENCE study and compare them with those from three cohorts in previously published analyses.^{3–5}

The median age of the children was 3.3 years (Table 1). Exposure to SARS-CoV-2 from an unknown source or from a source outside the child's family accounted for 55% of the cases of infection. A total of 12% of the children appeared ill, and 54% had a temperature of at least 37.6°C. Common symptoms were cough (in 44% of the patients) and no feeding or difficulty feeding (in 23%); the latter symptom occurred more often in children younger than 21 months of age. Fever, cough, or shortness of breath occurred in 28 of 54 of febrile patients (52%) (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). A total of 4% of the children had oxygen saturation values (as measured by pulse oximetry) of less than 95%; all these patients also had imaging evidence of lung involvement. Of the 9 patients who received respiratory support (Table S2), 6 had coexisting conditions. Laboratory and imaging findings are provided in Tables S3 and S4.

According to the categories described by Dong et al.,⁴ 21% of the patients were asymptomatic, 58% had mild disease, 19% had moderate disease, 1% had severe disease, and 1% were in critical condition (Table S5). Most of the infants presented with mild disease. Severe and critical cases were diagnosed in patients with coexisting conditions. No deaths were reported. A total of 38% of the patients were admitted to the hospital because of symptoms, irrespective of the severity of disease (Table 1).⁴

Among our patients, the incidence of transmission through apparent exposure to a family cluster was lower than that in other cohorts, possibly because of the late lockdown in Italy. As compared with the other cohorts, fewer patients in our cohort had moderate-to-severe disease, possibly because chest radiography was predominantly used and chest computed tomography was rarely used. Thus, fewer cases of diagnosed (subclinical) pneumonia may have been identified. Bedside lung ultrasonography by experienced sonographers was performed in only 10% of the patients, 90% of whom received a diagnosis of lung interstitial syndrome without further radiographic imaging.

Niccolò Parri, M.D.

Matteo Lenge, Ph.D.

Meyer University Children's Hospital
Florence, Italy
niccolo.parri@meyer.it

Danilo Buonsenso, M.D.

Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Italy

for the Coronavirus Infection in Pediatric
Emergency Departments (CONFIDENCE)
Research Group

A list of the members of the CONFIDENCE research group is provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.

Table 1. Epidemiologic Characteristics, Clinical Features, and Outcomes in the Italian CONFIDENCE Cohort as Compared with Other Cohorts.*

Characteristics	CONFIDENCE Study (N = 100)	Lu et al. ³ (N = 171)	Dong et al. ⁴ (N = 731)	CDC MMWR ⁵ (N = 2572) [†]
Median age (range) — yr	3.3 (0–17.5)	6.7 (1 day–15 yr)	7 (NA)	11 (0–17)
Age distribution — no. (%)				
<1 yr	40 (40.0)	31 (18.1)	86 (11.8)	398 (15.5)
1 to <6 yr	15 (15.0)	40 (23.4)	137 (18.7)	NA
6–10 yr	21 (21.0)	58 (33.9)	171 (23.4)	NA
>10 yr	24 (24.0)	42 (24.6)	337 (46.1)	NA
Sex — no./total no. (%)				
Female	43/100 (43.0)	67/171 (39.2)	311/731 (42.5)	1082/2490 (43.4)
Male	57/100 (57.0)	104/171 (60.8)	420/731 (57.5)	1408/2490 (56.5)
Coexisting conditions — no./total no. (%)	27/100 (27.0)	NA	NA	80/345 (23.2)
Exposure to SARS-CoV-2 — no./total no. (%)				
Family cluster	45/100 (45.0)	131/171 (76.6) [‡]	NA	168/184 (91.3)
Other exposure	48/100 (48.0)	2/171 (1.2)	NA	16/184 (8.7)
Unknown exposure	7/100 (7.0)	15/171 (8.8)	NA	0
Signs and symptoms in patients for whom data were available — no./total no. (%)	100/100 (100.0)	171/171 (100.0)	0	291/2572 (11.3)
Symptomatic on presentation in emergency department — no./total no. (%)	79/100 (79.0)	144/171 (84.0)	637/731 (87.1)	291/2572 (11.3)
Fever, cough, or shortness of breath — no./total no. (%)	28/54 (51.8)	NA	NA	213/291 (73.2)
Fever — no./total no. (%)	54/100 (54.0)	71/171 (41.5)	NA	163/291 (56.0)
Temperature — no./total no. (%) [§]				
≤37.5°C	46/100 (46.0)	100/171 (58.5)	NA	128/291 (44.0)
37.6–38.0°C	15/100 (15.0)	16/171 (9.4)	NA	NA
38.1–39.0°C	28/100 (28.0)	39/171 (22.8)	NA	NA
>39.0°C	11/100 (11.0)	16/171 (9.4)	NA	NA
Symptoms — no./total no. (%)				
Cough	44/100 (44.0)	83/171 (48.5)	NA	158/291 (54.3)
Shortness of breath	11/100 (11.0)	NA	NA	39/291 (13.4)
No feeding or difficulty feeding	23/100 (23.0)	NA	NA	NA
Rhinorrhea	22/100 (22.0)	13/171 (7.6)	NA	21/291 (7.2)

Drowsiness	11/100 (11.0)	NA	NA	NA	NA
Nausea or vomiting	10/100 (10.0)	NA	NA	NA	31/291 (10.6)
Fatigue	9/100 (9.0)	13/171 (7.6)	NA	NA	NA
Diarrhea	9/100 (9.0)	15/171 (8.8)	NA	NA	37/291 (12.7)
Dehydration	6/100 (6.0)	NA	NA	NA	NA
Abdominal pain	4/100 (4.0)	NA	NA	NA	17/291 (5.8)
Headache	4/100 (4.0)	NA	NA	NA	81/291 (27.8)
Sore throat	4/100 (4.0)	NA	NA	NA	71/291 (24.4)
Rash	3/100 (3.0)	NA	NA	NA	NA
Cyanosis	1/100 (1.0)	NA	NA	NA	NA
Apnea	1/100 (1.0)	NA	NA	NA	NA
Tachypnea¶	NA	49/171 (28.7)	NA	NA	NA
Tachycardia	NA	72/171 (42.1)	NA	NA	NA
Oxygen saturation <92% as measured by pulse oximetry — no./total no. (%)	1/100 (1.0)	4/171 (2.3)	NA	NA	NA
Outcome — no./total no. (%)					
Admitted	67/100 (67.0)	NA	NA	NA	147/2572 (5.7)
Admitted for signs and symptoms	38/100 (38.0)	NA	NA	NA	NA
Admitted and awaiting swab results	4/100 (4.0)	NA	NA	NA	NA
Admitted for isolation	25/100 (25.0)	NA	NA	NA	NA
Survived — no./total no. (%)	100/100 (100.0)	170/171 (99.4)	730/731 (99.9)	2569/2572 (99.9)	
Died — no./total no. (%)	0	1/171 (0.6)	1/731 (0.1)	3/2572 (0.1)	

* Percentages may not total 100 because of rounding. CDC MMWR denotes Centers for Disease Control and Prevention *Morbidity and Mortality Weekly Report*, CONFIDENCE Coronavirus Infection in Pediatric Emergency Departments, and NA not available.

† In the CDC MMWR cohort, data on sex, coexisting conditions, exposure to SARS-CoV-2 in family clusters and other exposure (including travel), and symptoms and signs were only partially available.

‡ Lu et al.³ reported that 131 children had exposure to family members with confirmed Covid-19 and 23 children had exposure to family members with suspected Covid-19.

§ Lu et al.³ reported temperature categories of less than 37.5 and 37.5 to 38.0.

¶ Tachypnea refers to a respiratory rate higher than the upper limit of the normal range, according to age. The normal ranges of respiratory rate (in breaths per minute) were as follows: 40 to 60 for newborns, 30 to 40 for children from 1 month to less than 1 year of age, 25 to 30 for those 1 to 3 years of age, 20 to 25 for those 4 to 7 years of age, 18 to 20 for those 8 to 14 years of age, and 12 to 20 for those older than 14 years of age.

|| Tachycardia refers to a pulse rate higher than the upper limit of the normal range, according to age. The normal ranges of pulse rate (in beats per minute) were as follows: 120 to 140 for newborns, 110 to 130 for children from 1 month to less than 1 year of age, 100 to 120 for those 1 to 3 years of age, 80 to 100 for those 4 to 7 years of age, 70 to 90 for those 8 to 14 years of age, and 60 to 70 for those older than 14 years of age.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on May 1, 2020, at NEJM.org.

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report 65. March 2020 (<https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200325-sitrep-65-covid-19.pdf>).
2. Italian National Health Institute (Istituto Superiore di Sanità). Coronavirus epidemic: situation report. March 26, 2020. (In Italian) (<https://www.epicentro.iss.it/coronavirus/bollettino/>

Bollettino-sorveglianza-integrata-COVID-19_26-marzo%202020.pdf).

3. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. *N Engl J Med* 2020;382:1663-5.
4. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics* 2020 March 16 (Epub ahead of print).
5. CDC COVID-19 Response Team. Coronavirus disease 2019 in children — United States, February 12–April 2, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:422-6.

DOI: 10.1056/NEJMc2007617

Correspondence Copyright © 2020 Massachusetts Medical Society.